|
CONSOLIDATED STATEMENTS OF CASH FLOWS |
| |||||||||
|
(Unaudited) |
| |||||||||
|
|
Three Months Ended |
|
Year Ended |
| ||||||
|
|
June 27, |
|
March 28, |
|
June 28, |
|
June 27, |
|
June 28, |
|
|
|
2015 |
|
2015 |
|
2014 |
|
2015 |
|
2014 |
|
|
|
(in thousands) |
| ||||||||
|
Cash flows from operating activities: |
|
|
|
|
|
|
|
|
|
|
|
Net income |
$ 98,659 |
|
$ 79,433 |
|
$ 84,793 |
|
$ 206,038 |
|
$ 354,810 |
|
|
Adjustments to reconcile net income to net cash provided by operating activities: |
|
|
|
|
|
|
|
|
|
|
|
Stock-based compensation |
17,709 |
|
18,586 |
|
21,786 |
|
79,491 |
|
85,452 |
|
|
Depreciation and amortization |
92,639 |
|
71,439 |
|
64,391 |
|
299,396 |
|
244,593 |
|
|
Deferred taxes |
(32,207) |
|
(15,658) |
|
(9,501) |
|
(72,507) |
|
(32,159) |
|
|
Loss (gain) from sale of property, plant and equipment |
(1,228) |
|
(441) |
|
1,068 |
|
419 |
|
2,187 |
|
|
Tax benefit (shortfall) related to stock-based compensation |
(861) |
|
7,635 |
|
942 |
|
8,155 |
|
(68) |
|
|
Impairment of long-lived assets |
517 |
|
5,522 |
|
6,447 |
|
67,010 |
|
11,644 |
|
|
Impairment of investments in privately-held companies |
94 |
|
- |
|
6,537 |
|
94 |
|
10,260 |
|
|
In-process research and development written-off |
- |
|
- |
|
- |
|
8,900 |
|
2,580 |
|
|
Loss (gain) on sale of business |
(35,849) |
|
- |
|
- |
|
(35,849) |
|
- |
|
|
Impairment of goodwill |
- |
|
- |
|
- |
|
84,110 |
|
- |
|
|
Excess tax benefit from stock-based compensation |
(2,372) |
|
(5,997) |
|
(4,897) |
|
(12,549) |
|
(14,192) |
|
|
Changes in assets and liabilities: |
|
|
|
|
|
|
|
|
|
|
|
Accounts receivable |
(417) |
|
(19,921) |
|
8,300 |
|
16,984 |
|
13,340 |
|
|
Inventories |
10,105 |
|
9,194 |
|
1,226 |
|
2,163 |
|
20,672 |
|
|
Other current assets |
15,338 |
|
(156) |
|
26,579 |
|
(8,783) |
|
45,557 |
|
|
Accounts payable |
2,874 |
|
477 |
|
5,203 |
|
(4,201) |
|
(11,255) |
|
|
Income taxes payable |
39,217 |
|
22,587 |
|
9,853 |
|
62,350 |
|
54,492 |
|
|
Deferred revenue on shipments to distributors |
(223) |
|
3,447 |
|
1,475 |
|
4,593 |
|
(823) |
|
|
All other accrued liabilities |
17,793 |
|
5,917 |
|
9,882 |
|
(12,110) |
|
(10,983) |
|
|
Net cash provided by (used in) operating activities |
221,788 |
|
182,064 |
|
234,084 |
|
693,704 |
|
776,107 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash flows from investing activities: |
|
|
|
|
|
|
|
|
|
|
|
Purchase of property, plant and equipment |
(15,360) |
|
(10,185) |
|
(23,654) |
|
(75,816) |
|
(132,523) |
|
|
Proceeds from sales of property, plant and equipment |
2,741 |
|
1,615 |
|
1,627 |
|
29,035 |
|
5,293 |
|
|
Proceeds from sale of business |
35,550 |
|
- |
|
- |
|
35,550 |
|
- |
|
|
Proceeds from maturity of available-for-sale securities |
- |
|
- |
|
- |
|
- |
|
27,000 |
|
|
Purchases of available-for-sale securities |
- |
|
- |
|
(49,953) |
|
(25,142) |
|
(49,953) |
|
|
Purchases of privately-held companies securities |
- |
|
(200) |
|
- |
|
(200) |
|
- |
|
|
Payments in connection to acquisitions |
- |
|
- |
|
- |
|
- |
|
(459,256) |
|
|
Proceeds from sale of investments in privately-held companies |
- |
|
500 |
|
- |
|
500 |
|
- |
|
|
Net cash provided by (used in) investing activities |
22,931 |
|
(8,270) |
|
(71,980) |
|
(36,073) |
|
(609,439) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash flows from financing activities: |
|
|
|
|
|
|
|
|
|
|
|
Excess tax benefit from stock-based compensation |
2,372 |
|
5,997 |
|
4,897 |
|
12,549 |
|
14,192 |
|
|
Contingent consideration paid |
- |
|
- |
|
- |
|
- |
|
(4,705) |
|
|
Dividends paid |
(79,558) |
|
(79,419) |
|
(73,626) |
|
(317,909) |
|
(294,175) |
|
|
Repayment of notes payable |
- |
|
- |
|
(2,430) |
|
(437) |
|
(4,708) |
|
|
Issuance of debt |
- |
|
- |
|
- |
|
- |
|
497,895 |
|
|
Debt issuance cost |
- |
|
- |
|
- |
|
- |
|
(3,431) |
|
|
Repurchase of common stock |
(35,963) |
|
(36,774) |
|
(40,744) |
|
(195,088) |
|
(305,314) |
|
|
Issuance of ESPP shares under employee stock purchase program |
22,298 |
|
- |
|
23,713 |
|
40,951 |
|
42,809 |
|
|
Net issuance of restricted stock units |
(7,428) |
|
(8,369) |
|
(8,922) |
|
(30,657) |
|
(31,384) |
|
|
Proceeds from stock options exercised |
12,328 |
|
31,098 |
|
26,232 |
|
61,453 |
|
69,639 |
|
|
Net cash provided by (used in) financing activities |
(85,951) |
|
(87,467) |
|
(70,880) |
|
(429,138) |
|
(19,182) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net increase (decrease) in cash and cash equivalents |
158,768 |
|
86,327 |
|
91,224 |
|
228,493 |
|
147,486 |
|
|
Cash and cash equivalents: |
|
|
|
|
|
|
|
|
|
|
|
Beginning of period |
1,392,197 |
|
1,305,870 |
|
1,231,248 |
|
1,322,472 |
|
1,174,986 |
|
|
End of period |
$ 1,550,965 |
|
$ 1,392,197 |
|
$ 1,322,472 |
|
$ 1,550,965 |
|
$ 1,322,472 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total cash, cash equivalents and short-term investments |
$ 1,626,119 |
|
$ 1,467,339 |
|
$ 1,372,425 |
|
$ 1,626,119 |
|
$ 1,372,425 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|